Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aspirin for COVID-19
NCT04365309Phase 3Unknown
- Sponsor
- Xijing Hospital
- Start
- Feb 2020
- Primary completion
- Apr 2020
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of aspirin in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Xijing Hospital. Primary endpoints: Clinical Recovery Time at 14 days and Time of SARS-CoV2 Overcasting at 37 days. Status: unknown.
02
Drugs
aspirin
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04365309.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04365309.